The Cytoskeleton Regulatory Protein hMena (ENAH) Is Overexpressed in Human Benign Breast Lesions with High Risk of Transformation and Human Epidermal Growth Factor Receptor-2–Positive/Hormonal Receptor–Negative Tumors

Purpose: hMena (ENAH), a cytoskeleton regulatory protein involved in the regulation of cell motility and adhesion, is overexpressed in breast cancer. The aim of this study was to define at what stage of breast carcinogenesis hMena is overexpressed and to correlate hMena overexpression with established prognostic factors in breast cancer, focusing on human epidermal growth factor receptor-2 (HER-2). Experimental Design: hMena expression was assessed immunohistochemically in a prospective cohort of cases (n = 360) encompassing a highly representative spectrum of benign breast diseases associated with different risk of transformation, in situ, invasive, and metastatic tumors. Correlations with conventional pathologic and prognostic variables, such as proliferation index, hormonal receptor status, and HER-2 overexpression, were also evaluated. In vitro experiments were done to study the effect of neuregulin-1 and Herceptin treatments on hMena expression. Results: hMena protein is undetectable in normal breast and is weakly expressed in a small percentage of low-risk benign diseases (9%), but displays a progressive and significant increase of positivity in benign lesions at higher risk of transformation (slightly increased risk 43%; moderate increased risk 67%), in in situ (72%), invasive (93%), and metastatic breast cancer (91%). A significant direct correlation with tumor size (P = 0.04), proliferation index (P < 0.0001), and HER-2 overexpression (P < 0.0001) and an inverse relationship with estrogen (P = 0.036) and progesterone receptors (P = 0.001) are found in invasive carcinomas. In vitro experiments show that neuregulin-1 up-regulates, whereas Herceptin down-regulates, hMena expression. Conclusions: Our data provide new insights into the relevance of actin-binding proteins in human breast carcinogenesis and indicate hMena overexpression as a surrogate indicator in breast disease management.

[1]  D. Hanein,et al.  Ena/VASP Proteins Enhance Actin Polymerization in the Presence of Barbed End Capping Proteins*[boxs] , 2005, Journal of Biological Chemistry.

[2]  R. Schreiber,et al.  A critical function for type I interferons in cancer immunoediting , 2005, Nature Immunology.

[3]  J. Manson,et al.  Vitamin E in the Primary Prevention of Cardiovascular Disease and Cancer: The Women’s Health Study: A Randomized Controlled Trial , 2005, JAMA.

[4]  C. Stove,et al.  Roles for neuregulins in human cancer , 2005, Clinical & Experimental Metastasis.

[5]  Piero Musiani,et al.  Gene expression analysis of immune-mediated arrest of tumorigenesis in a transgenic mouse model of HER-2/neu-positive basal-like mammary carcinoma. , 2005, The American journal of pathology.

[6]  J. Rao,et al.  Green Tea Extract Modulates Actin Remodeling via Rho Activity in an In vitro Multistep Carcinogenic Model , 2005, Clinical Cancer Research.

[7]  C. Shriver,et al.  Genomic instability in histologically normal breast tissues: implications for carcinogenesis. , 2004, The Lancet. Oncology.

[8]  John S. Condeelis,et al.  Identification and Testing of a Gene Expression Signature of Invasive Carcinoma Cells within Primary Mammary Tumors , 2004, Cancer Research.

[9]  C. Mason,et al.  Mena and Vasodilator-Stimulated Phosphoprotein Are Required for Multiple Actin-Dependent Processes That Shape the Vertebrate Nervous System , 2004, The Journal of Neuroscience.

[10]  S. Ramaswamy,et al.  Twist, a Master Regulator of Morphogenesis, Plays an Essential Role in Tumor Metastasis , 2004, Cell.

[11]  J. Rao,et al.  Microfilament actin remodeling as a potential target for cancer drug development. , 2004, Current cancer drug targets.

[12]  M. Mottolese,et al.  Human mena protein, a serex‐defined antigen overexpressed in breast cancer eliciting both humoral and CD8+ T‐cell immune response , 2004, International journal of cancer.

[13]  J. Loureiro,et al.  Ena/VASP proteins: regulators of the actin cytoskeleton and cell migration. , 2003, Annual review of cell and developmental biology.

[14]  J. Theriot,et al.  Ena/VASP proteins contribute to Listeria monocytogenes pathogenesis by controlling temporal and spatial persistence of bacterial actin‐based motility , 2003, Molecular microbiology.

[15]  Gottfried Konecny,et al.  Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer. , 2003, Journal of the National Cancer Institute.

[16]  E. Petricoin,et al.  Proteomics of human breast ductal carcinoma in situ. , 2002, Cancer research.

[17]  Gary G. Borisy,et al.  Antagonism between Ena/VASP Proteins and Actin Filament Capping Regulates Fibroblast Motility , 2002, Cell.

[18]  R. Bast,et al.  2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  Elaine Fuchs,et al.  Directed Actin Polymerization Is the Driving Force for Epithelial Cell–Cell Adhesion , 2000, Cell.

[20]  D. Henson,et al.  Benign breast changes and the risk for subsequent breast cancer: an update of the 1985 consensus statement. Cancer Committee of the College of American Pathologists. , 1998, Archives of pathology & laboratory medicine.

[21]  J. Mendelsohn,et al.  Heregulin Regulates Cytoskeletal Reorganization and Cell Migration through the p21-activated Kinase-1 via Phosphatidylinositol-3 Kinase* , 1998, The Journal of Biological Chemistry.

[22]  M. Mariani,et al.  Production and characterization of murine mAbs to the extracellular domain of human neu oncogene product GP185HER2. , 1992, Hybridoma.

[23]  F. Tarentini Trojani.  [Tumors of the breast]. , 1987, La Clinica terapeutica.

[24]  J. Berg,et al.  TUMORS of the breast. I. , 1954, Medical times.